CG Oncology, Inc. (CGON)
| Market Cap | 2.88B |
| Revenue (ttm) | 551,000 |
| Net Income (ttm) | -128.08M |
| Shares Out | 76.25M |
| EPS (ttm) | -1.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,241,575 |
| Open | 36.48 |
| Previous Close | 35.76 |
| Day's Range | 35.79 - 38.91 |
| 52-Week Range | 14.80 - 40.47 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 64.25 (+70.33%) |
| Earnings Date | Nov 11, 2025 |
About CGON
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretost... [Read more]
Financial Performance
In 2024, CG Oncology's revenue was $1.14 million, an increase of 458.33% compared to the previous year's $204,000. Losses were -$88.04 million, 29.9% more than in 2023.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for CGON stock is "Strong Buy." The 12-month stock price target is $64.25, which is an increase of 70.33% from the latest price.
News
CG Oncology, Inc. (CGON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
CG Oncology, Inc. (NASDAQ:CGON) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Arthur Kuan - Chairman & CEO Ambaw Bellete - President & COO...
CG Oncology Stock Signals Bullish Momentum Ahead
CG Oncology CGON has moved into Phase 2 of its 18-phase Adhishthana cycle, a critical stage that often sets the tone for early bullish momentum. Within this phase, the stock transitions into what's ca...
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Ca...
CG Oncology Completes Enrollment in PIVOT-006
– Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) –– One of the largest randomized phase 3 studies in this patient population will encompas...
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Ini...
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)
CG Oncology, Inc.'s cretostimogene shows strong efficacy and safety in late-stage bladder cancer trials, with promising complete response rates and durable activity. The company boasts a robust cash p...
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signa...
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74....
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
CG Oncology, Inc. reported positive phase 3 BOND-003 results for Cretostimogene in treating BCG-unresponsive NMIBC, presented at the SUO 25th Annual Meeting. The company aims to use Cretostimogene as ...
CG Oncology Announces Pricing of Public Offering
IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology Announces Proposed Public Offering
IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer
An experimental immunotherapy drug is a potentially effective treatment for patients with bladder cancer who no longer respond to current therapies, researchers reported on Thursday at the Society of ...
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
SCHAUMBURG, Ill. and IRVINE, Calif.
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladd...
CG Oncology: Promising Data, But Looks Expensive
CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by sele...
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Natur...
CG Oncology Bringing Undervalued Innovation To Bladder Cancer
CG Oncology's cretostimogene shows high potential to disrupt the NMIBC market with promising efficacy and safety data. The company is initially targeting high-risk NMIBC patients who no longer respond...
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab